Comparative Pharmacology
Head-to-head clinical analysis: VISKAZIDE versus ZIAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VISKAZIDE versus ZIAC.
VISKAZIDE vs ZIAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Viskazide is a combination of pindolol (a non-cardioselective beta-blocker with intrinsic sympathomimetic activity) and hydrochlorothiazide (a thiazide diuretic). Pindolol competitively blocks beta-1 and beta-2 adrenergic receptors, reducing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide inhibits the Na+/Cl- symporter in the distal convoluted tubule, decreasing sodium and water reabsorption, leading to reduced plasma volume and blood pressure.
ZIAC is a combination of bisoprolol, a cardioselective beta1-adrenergic receptor blocker, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing blood volume.
Oral: 1 tablet (pindolol 10 mg / hydrochlorothiazide 25 mg) once daily; may increase to 2 tablets once daily if needed.
ZIAC (bisoprolol fumarate/hydrochlorothiazide) 2.5 mg/6.25 mg to 10 mg/6.25 mg orally once daily, titrated at 2-week intervals based on blood pressure response. Maximum dose: 20 mg/12.5 mg per day.
None Documented
None Documented
Terminal elimination half-life is 10-12 hours for the hydrochlorothiazide component and 4-6 hours for pindolol; clinical context: steady-state achieved in 2-3 days for pindolol and 3-5 days for hydrochlorothiazide.
Bisoprolol: 9–12 h (terminal); HCTZ: 6–15 h (terminal); prolonged in renal impairment; steady state by 5 days
Renal elimination (approximately 70% unchanged), with the remainder as inactive metabolites; biliary/fecal excretion is minor (<10%).
Renal: bisoprolol (50% unchanged), HCTZ (≥95% unchanged); biliary/fecal: bisoprolol (≤2%)
Category C
Category C
Beta Blocker/Thiazide Diuretic Combination
Beta Blocker + Diuretic